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Intensive care unit recovery clinics (ICU-RCs) have been proposed as a potential
mechanism to address the multifaceted unmet needs of intensive care unit (ICU)
survivors and caregivers. The needs of this population include, but are not limited
to, medication optimization, addressing physical function and psychological needs,
coordination of care, and other interventions that may help in improving patient
recovery and reducing the rate of preventable readmissions. The objective of this
opinion paper is to identify and describe clinical pharmacy services for the manage-
ment of ICU survivors and their caregivers in an ICU-RC. The goals are to guide
the establishment and development of clinical pharmacist involvement in ICU-RCs
and to highlight ICU recovery research and educational opportunities. Recommen-
dations provided in this paper are based on the following: a review of published
data on clinical pharmacist involvement in the ICU-RCs; a consensus of clinical
pharmacists who provide direct patient care to ICU survivors and caregivers; and a
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review of published guidelines and literature focusing on the management of ICU
survivors and caregivers. These recommendations define areas of clinical pharma-
cist involvement in ICU-RCs. Consequently, clinical pharmacists can promote edu-
cation on Post Intensive Care Syndrome and Post Intensive Care Syndrome-Family;
improve medication adherence; facilitate appropriate referrals to primary care
providers and specialists; ensure comprehensive medication management and
medication reconciliation; provide assessment of inappropriate and appropriate
medications after hospitalization; address adverse drug events, medication errors,
and drug interactions; promote preventive measures; and facilitate medication
acquisition with the goal of improving patient outcomes and reducing health care
system costs.
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transitions of care
1 | INTRODUCTION
More than 5.7 million intensive care unit (ICU) admissions occur annu-
ally in the United States with a reported survival rate of 71% to 90% in
adults.1 Among adult ICU survivors, reported readmission rates were
15% at 30 days, 26% at 90 days, and 43% at 1 year.2 Forty-five percent
of these patients had increased resource utilization. In addition to
readmissions, ICU survivors are at increased risk of mortality and
decreased quality of life compared with the overall population.3 ICU
survivors may experience several complications following their hospital-
ization. These complications can include new or worsening cognitive
impairment (greater than 75%), mental health conditions (up to 62%),
physical disabilities (ICU-acquired neuromuscular weakness reported in
greater than 25%), financial issues (33%-50%), and social impairment.4,5
Given the high, and often overlapping frequency of these post-ICU
morbidities, the Society of Critical Care Medicine (SCCM) developed
the term “Post Intensive Care Syndrome” (PICS) to identify the pres-
ence of one or more of these impairments for ICU survivors and their
caregivers.4,5 PICS is defined as “new or worsening impairments in
physical, cognitive, or mental health status arising after critical illness
and persisting beyond acute care hospitalization.” Post-intensive care
syndrome is also seen in caregivers, denoted by the term Post Intensive
Care Syndrome-Family (PICS-F).4,5 PICS and PICS-F are considered a
public health burden; however, the true impact of these syndromes to
patients, their families, and the general public is unknown.
In addition to PICS, this population may be challenged with re-
introduction to society, financial insecurities associated with daily liv-
ing expenses and health care costs, loss of job or job obtainment, low
health literacy, and management of current and new chronic condi-
tions. Furthermore, those unable to return home immediately follow-
ing their ICU stay may undergo a complicated sequence of care
transitions (eg, skilled nursing facility) increasing the risk of problems
at each transition.
1.1 | Medication-related problems
During transitions of care of ICU patients, medications are frequently
initiated, discontinued, or adjusted, especially in the setting of multi-
faceted pathophysiological and physiological changes (eg, renal insuf-
ficiency, acute liver injury, hypotension) that often occur during a
critical illness. ICU survivors are often discharged from the hospital
with new medical diagnoses, increased medication regimen complex-
ity, decreased physical or cognitive function, and increased self-
management responsibilities related to medication use. These medica-
tion and health-related changes can also impose further burdens on
caregivers.6 Additionally, patients may be initiated on medications
during their critical illness that are often inappropriately continued,
exposing them to harmful and unnecessary medication side effects.7
Currently, there are limited data evaluating medication-related
problems (MRPs) identified during these transitions. One multicenter,
retrospective study (58 ICUs; N = 985) showed that almost half of
patients experienced medication errors (MEs) during transition from
ICU to non-ICU locations.8 Common MEs included medication continu-
ation with ICU-only indication (28.4%), untreated condition (19.4%),
and medication without indication (11.9%). There have been several
studies evaluating medication-related interventions during these transi-
tions. These interventions included deprescribing of ICU-initiated medi-
cations such bronchodilators, atypical antipsychotics, and stress ulcer
prophylaxis, as well as re-initiation of home medications.9-12 Therefore,
it is crucial to review patients' medication lists to ensure they are receiv-
ing appropriate medications during each transition of care.
1.2 | ICU recovery clinics
ICU survivors are usually cared for by primary care physicians (PCPs)
and/or specialists, depending on their comorbidities, when discharged
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from the hospital and followed in the outpatient setting.13 Unfortu-
nately, the shortage of PCPs and sparse availability of specialized
clinics designed specifically for post-ICU care may limit a provider's
ability to dedicate sufficient time to provide extensive disease state
and medication counseling in ICU survivors.14 Many health care pro-
fessionals may not be able to appropriately manage and treat ICU sur-
vivors because of the complexity and unfamiliarity of care required in
these patients. Additionally, ICU survivors are frequently those with
complex medical conditions under the care of multiple specialties.13
This can lead to hesitancy in adjustment of therapies without input
from those specialists. Therefore, appropriate coordination of care is
required to care for these patients. These issues helped to provide one
aspect of the foundation for SCCM to develop the THRIVE Collabora-
tive, an initiative which aimed to improve care and provide support for
ICU survivors and caregivers.15 The THRIVE Collaborative's mission is
to provide education to ICU and non-ICU medical providers about
PICS, to lead the establishment of support groups for survivors of criti-
cal illness and their families, and to lead the development of ICU-RCs.
More recently, the Critical and Acute Illness Recovery Organization
(CAIRO) was developed to help improve outcomes for ICU survivors
and their families.16 These organizations called on health care systems
to address how to care for these high-risk patients and caregivers,
especially with the potential risk of deterioration and readmission.3
ICU-RCs have been proposed as a potential mechanism to address
the multifaceted unmet needs of ICU survivors and caregivers. The needs
of this population include, but are not limited to, medication optimization,
addressing physical function and psychological needs, coordination of
care, and other interventions that may help in improving patient recovery
and reducing the rate of preventable readmissions. The ICU-RC team
often consists of an interprofessional group aimed at identifying and
treating many complications impacting ICU survivors, and in some cases,
caregivers. Various specialties may make up the interprofessional team
including critical care intensivists, advanced practice providers, nurses,
respiratory therapists, physical and/or occupational therapists, psycholo-
gists, social workers, and clinical pharmacists. One study showed no signif-
icant difference in readmission rates in patients receiving care through the
interprofessional ICU-RC vs usual care (14.4% vs 21.5%; P = 0.16); how-
ever, early readmissions within 7 days was lower in the ICU-RC group.17
As ICU-RCs are developed to address the needs of ICU survivors
with often new and complex medication regimens, clinical pharmacists
should be key members of ICU-RC staff. Clinical pharmacists, especially
critical care clinical pharmacists,18-20 practicing in this setting contrib-
ute an important skill set to appropriately assess potential MRPs,
address PICS, assist with medication procurement issues, and educate
patients on their medication-related issues. As pharmacotherapeutic
experts, clinical pharmacists are uniquely poised to perform high qual-
ity medication reconciliation accompanied by real time medication
therapy recommendations and regimen modifications to promote med-
ication safety and adherence.4,21,22
The purpose of this opinion paper is to describe the practice and
scope of clinical services provided by clinical pharmacists in ICU-RCs.
Specifically, the goals of this paper are to describe the roles and activi-
ties of clinical pharmacists within ICU-RCs, to outline studies that
have shown gaps in care and where clinical pharmacists can impact
care, to outline potential strategies to develop a position proposal for
ICU-RC clinical pharmacists, and to provide guidance on rec-
ommended training and competencies of ICU-RC clinical pharmacists.
Recommendations of this opinion paper were based on the following:
a review of published data on clinical pharmacist involvement in the
management of ICU survivors and caregivers; a consensus of clinical
pharmacists who provide direct patient care to ICU survivors and
caregivers and practice in different pharmacy models, including
community-based and academic settings; and a review of published
guidelines and literature focusing on the management of ICU survi-
vors and caregivers.
2 | DEVELOPING ROLES AND
RESPONSIBILITIES OF THE ICU-RC CLINICAL
PHARMACIST
2.1 | Clinical pharmacist roles
It is important to understand the current role and activities of an ICU-
RC clinical pharmacist prior to development and implementation of a
clinical pharmacist service in an ICU-RC. One survey based study
described the activities of clinical pharmacists in ICU-RCs (n = 9).23
This study reported that all the clinical pharmacists are critical care
trained and most of them serve within the clinic setting in addition to
their ICU practice. Many ICU-RC clinical pharmacists are embedded
within the clinic and see each patient scheduled for physician appoint-
ments, while others may only see patients based on referral. All clini-
cal pharmacists reported that direct patient care was provided during
every patient visit. Research, patient enrollment, clinic design, and
administrational activities were other roles clinical pharmacists were
involved in outside of direct patient care. During the patient visit,
78% of clinical pharmacists reported that they always conducted med-
ication reconciliation. Other activities and description of the clinics
and clinical pharmacist activities are listed in Tables 1 and 2.
Within the area of ICU recovery, there is a definitive role for clini-
cal pharmacist services to address survivors' medication-related
needs. Several studies support the role of a clinical pharmacist within
the ICU-RCs. These studies reported that clinical pharmacist interven-
tions in the ICU-RCs included the identification and management of
MRPs, which often involved: 1. Inappropriate discontinuation of
chronic medications at hospital discharge, 2. Inappropriate continua-
tion of medications (eg, proton pump inhibitors, antipsychotics),
3. Medication access issues, 4. Lack of information and understanding
of information, 5. Difficulties with medication administration, 6. Issues
with medication suitability, 7. Adverse drug events (ADEs) and pre-
ventative measures, 8. Need for preventative care (eg, vaccinations),
and 9. Smoking cessation.6,13,17,24 Overall, studies show that an ICU-
RC clinical pharmacist addresses the unmet medication-related needs
of ICU survivors.
Ideally, the clinical pharmacist in an ICU-RC would be the critical
care pharmacist practicing both in the ICU and ICU-RC. Critical care
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clinical pharmacists are recognized as integral members of the ICU
team, and these pharmacists have extensive knowledge of PICS/
PICS-F and disease states and treatments that put ICU survivors at
risk of PICS and MRPs.18-20 This places critical care clinical pharma-
cists in an ideal position for their role in ICU-RCs and to educate
patients on potential complications related to a patient's ICU stay.
Therefore, critical care clinical pharmacists can help bridge the transi-
tion from inpatient to ambulatory care settings.
2.2 | Description of activities in ICU-RCs
Specific core activities determined by this consensus group of a clini-
cal pharmacist in the ICU-RC include: 1. Comprehensive medication
TABLE 1 Demographics and description of current clinical
pharmacy services in intensive care unit-recovery clinics23
Clinical pharmacists characteristics n = 9
Education completed, n (%)
Doctor of pharmacy (Pharm.D.) 8 (89)
PGY-1 pharmacy practice residency 8 (89)
PGY-2 critical care residency 7 (78)
Both PGY1 and PGY2 7 (78)
Fellowship training 1 (11%)
Master's degree in clinical pharmacy 1 (11%)








Both BCPS and BCCCP 4 (44%)
ICU-RCs characteristics n = 9
Location, n (%)
Academic medical center 9 (100%)
Additional affiliation with community hospital 1 (11%)




Team members, n (%)




Physical therapist 4 (44%)
Social worker 4 (44%)
Occupational therapist 3 (33%)
Respiratory therapist 3 (33%)
Nurse practitioner 2 (22%)
Case manager 2 (22%)
Communication methods, n (%)
Face-to-face 9 (100%)
Case conference 4 (44%)
Email 3 (33%)
Written documentation via EHR 2 (22%)
Teleconference 2 (22%)
Clinical pharmacist roles, n (%)
Direct patient care 9 (100%)
Research 8 (89%)
Clinic design 4 (44%)
Clinic governance or administration 4 (44%)
Patient selection and enrollment 1 (11%)
Direct patient care activities, n (%)
Conducted medication reconciliation (always) 78%
TABLE 1 (Continued)
Clinical pharmacists characteristics n = 9
Identified and addressed need for medication
education (often or routinely)
89%
Identified and addressed medication adherence
problems (often or routinely)
78%
Identified and addressed adverse drug effects
(often or routinely)
78%
Identified and addressed subtherapeutic
medication dosing (often or routinely)
56%
Identified and addressed medication use without
an indication (often or routinely)
44%
Identified and addressed failure to receive
medication after hospital discharge (often or
routinely)
44%
Identified and addressed need for preventive
interventions (often or routinely)
44%
Abbreviations: BCCCP, board certified critical care pharmacist; BCNSP,
board certified nutrition support pharmacist; BCPS, board certified phar-
macotherapy specialist; EHR, electronic health record; ICU, intensive care
unit; ICU-RC, intensive care unit-recovery clinic; PGY-1, post-graduate
year one; PGY-2, post-graduate year two; SD, standard deviation.
TABLE 2 Description of clinical pharmacy activities in intensive
care unit-recovery clinics
Comprehensive medication and disease evaluation
Patient education and counseling
Adherence evaluation
Preventive care
Transitions of care activities
Referral to other services
Documentation
Education to health care professionals and learners
Development of tools and reference regarding Post-ICU Care and
PICS/PICS-F
Research
Abbreviations: ICU, intensive care unit; PICS, post-intensive care syn-
drome; PICS-F, post-intensive care syndrome family.
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management (CMM) and disease evaluation, 2. Patient education and
counseling, 3. Preventative care, 4. Transition of care activities,
5. Referral to other services, 6. Education to other health care profes-
sionals and learners, and 7. Other ICU-RC related activities. Details on
each specific activity will be described below.
2.2.1 | Comprehensive medication and disease
management
The ICU-RC clinical pharmacist caring for ICU survivors and caregivers
ideally perform CMMs, consisting of a thorough evaluation of a patient's
known disease states and all active medications. The CMM should
include assessment of patient's medication-related needs, evaluation of
patient's medication therapy by optimizing therapy (eg, identifying and
addressing MRPs, assessing efficacy and safety of each medication,
assessing medication-taking behaviors), development and implementa-
tion of a care plan in collaboration with the patient and their providers,
and performance of follow-up evaluations and provide medication moni-
toring plans.25 Through CMM, the clinical pharmacist may identify
opportunities for pharmacologic interventions. Pharmacologic interven-
tions may include, but are not limited to,: (1) Deprescribing; (2) Optimiza-
tion of drug therapy associated with the patient's indication prior to ICU
admission; (3) Assessment and tolerance of new medications initiated
during the ICU admission continued at discharge; (4) Evaluation of
adherence and addressing issues with adherence; and (5) Pharmacologic
treatment of complications associated with PICS.
Deprescribing
Patients who present for follow up in the ICU-RC often are prescribed
complex medication regimens inclusive of home medications prior to
admission, new acute and chronic medications as a result of the admis-
sion, and medications inappropriately continued from the hospitaliza-
tion.26 One study demonstrated approximately 50% of older adults
during post-transition home care visits were observed to meet criteria
for polypharmacy (5-9 prescribed medications) and almost 40% qualified
for hyperpolypharmacy (greater than 10 prescribed medications).27 Inap-
propriate continuation of medications from hospitalization has been
shown to significantly increase the burden of medication regimens for
this patient population.28-31 Clinical pharmacists working within ICU-
RCs are ideally suited to assess each patient's medication regimen for
medications which were inappropriately continued after hospital dis-
charge, in addition to potential simplification of medication regimens.
Therapy optimization
The ICU-RC is an optimal setting for a clinical pharmacist to assess
appropriateness of a patient's medication regimens for chronic disease
states. Often, patients have been admitted to the ICU for a decom-
pensation or exacerbation of a chronic condition, which may or may
not have been appropriately managed prior to admission. An example
of a clinical pharmacist intervention in this area is ensuring patients
are on appropriate controller inhalers after an exacerbation of asthma
or chronic obstructive pulmonary disease. Additionally, a clinical
pharmacist intervention could include initiation of chronic medications
for disease states that may not have been restarted at hospital dis-
charge depending on the patient's condition (eg, antihypertensive
medications for patients who were hypotensive at discharge). An ICU-
RC clinical pharmacist can assess for appropriateness of restarting
these medications in coordination with other specialists if needed.
Data relating to preventing readmissions with clinical pharmacist
intervention in an ICU-RC is lacking; however, reduction of
readmissions has been previously demonstrated with clinical pharma-
cist intervention after hospital discharge.32,33
Adverse effect assessment
Patients who present to ICU-RCs often have had multiple new medi-
cations initiated. The ICU-RC is an ideal setting to determine toler-
ance of these new medications with a focus on patients' potential
ADEs. Additionally, clinical pharmacists can evaluate for ADEs as
patients attempt to transition back to an out-of-hospital routine (eg,
changes in nutrition, sleep/wake cycles, and exercise/mobility). All of
these routine changes could impact the ADE profile of medications.
Clinical pharmacists in this setting can educate patients on whether
these ADEs are typical and/or expected to be short in duration, high-
light ways to mitigate these ADEs when possible, or facilitate chang-
ing medication regimens if ADEs are prohibitive.
Adherence evaluation
Clinical pharmacists are crucial in assessing and educating patients
on medication adherence. In groups of patients with chronic dis-
ease states (eg, diabetes), pharmacist-led programs have been
shown to improve medication adherence.34,35 Clinical pharmacists
should use tools to assist patients in achieving adherence, including
pill boxes, medication adherence packaging, reminder alarms, and
engaging supportive caregivers, if a need is identified. Clinical phar-
macists should also assess whether patients have adequate medica-
tion storage areas and stress the importance of appropriately
storing their medications. Additionally, patients should be counseled
on correct time of administration and frequency of specific medica-
tions, and drug-drug and drug-food interactions. The post-ICU set-
ting is also an opportunity to address patient's beliefs and
perceptions about their medications that could be potential barriers
to adherence. By putting patients at the center of these discus-
sions, clinical pharmacists can encourage informed adherence and
improve overall outcomes.
Treatment of complications associated with PICS
Patients with PICS often present with significant symptoms of
cognitive impairment, major depressive disorder, anxiety, and post-
traumatic stress disorder.4,5 Pharmacologic treatment is often a
component of managing these complications, particularly use of anti-
depressants, anxiolytics, and anti-psychotics. Clinicians practicing in
this setting may manage newly diagnosed or worsening depression
and/or anxiety by referral to other services, initiation or titration of
medications, and/or cognitive behavioral therapy. Clinical pharmacists
in ICU-RCs can assist providers with multiple pharmacotherapy issues,
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including selection of appropriate agents and dosing, cross titration of
one anti-depressant to an alternative, patient education and counsel-
ing, and/or deprescribing if necessary.
2.2.2 | Patient education and counseling
Within ICU-RCs, clinical pharmacists are ideally placed to educate ICU
survivors and caregivers about medication-related needs and prob-
lems, as well as appropriate medication storage and disposal. As an
integral clinician on the interprofessional team, clinical pharmacists
should provide patient-specific drug and disease state education dur-
ing initial and follow-up visits. Following an ICU admission, patients'
medications may have changed, new medicines may have been
started, and some pre-hospital medicines may have been
stopped.11,36-39 It is vital that patients and caregivers understand the
reasons for these changes to ensure that they can make informed
decisions about their care. Additionally, ICU-RC clinical pharmacists
should educate ICU survivors and caregivers on potential complica-
tions related to a patient's ICU stay and the risk of PICS and PICS-F.
2.2.3 | Preventative care
During an ICU stay, patients may receive treatment for a myriad of
disease states. Some of these disease states and treatments may place
them at increased risk for future complications. Preventive treatments
can be considered in the ICU if appropriately identified; however, they
may be deferred for multiple reasons. One of the main reasons vacci-
nations may not be administered in the ICU is the patient's immune
status. Relative and overt immunosuppression are common findings in
critically ill patients.40 Live vaccines have the potential to cause dis-
ease in the immunosuppressed population. Patients may not be able
to mount an appropriate immune response to vaccinations if they
have primary or secondary immunodeficiencies.41 Fever may develop
after vaccination and may be misinterpreted as a new infection. Addi-
tionally, vaccination practices vary from institution to institution, with
many opportunities for intervention.42
This provides a clear opportunity for an ICU-RC clinical pharma-
cist to ensure patients' vaccinations are up to date. The ICU-RC clini-
cal pharmacist should screen patients at each encounter for the
following, which include, but are not limited to, vaccine status for
influenza, varicella, meningococcal, pneumococcal, and Haemophilus
influenzae. Other vaccination opportunities include hepatitis A and B,
and tetanus, diphtheria, and pertussis. Particular focus should be paid
to comorbidities and details of patients' ICU stay to ensure all eligible
vaccines are identified and offered.
2.2.4 | Transitions of care activities
The ICU-RC clinical pharmacist can play a vital role in the management
of ICU survivors transferring from one setting to another (eg, from
hospital to home). In addition to medication-related education, clinical
pharmacists can assist ICU survivors and caregivers with re-entering
society and managing day-to-day tasks that can be impacted by PICS.
One example includes educating patients on how they take their med-
ications while managing their day to day tasks. Clinical pharmacists are
also well positioned during these transitions to ensure therapy contin-
uation by identifying these medications through medication reconcilia-
tion and by facilitating medication acquisition (eg, assisting with prior
authorizations, processing test prescriptions). Studies have shown that
more accurate and comprehensive medication histories are obtained
by pharmacy personnel compared with other health care profes-
sionals.43,44 In addition to medication reconciliation, ICU-RC clinical
pharmacists should also liaise with patients' primary care and/or com-
munity clinical pharmacists to improve continuity of care. Overall,
ICU-RC clinical pharmacists can serve as an integral player to facilitate
and address MRPs in ICU survivors during these transitions.
2.2.5 | Recommendation for referral to other
services
A reciprocal relationship between clinical pharmacists and patients
was described previously in which patients developed a reliance on
the clinical pharmacist as a trusted health care professional.45 It is
through these relationships of trust and significance that clinical phar-
macists may identify needs not previously identified by other mem-
bers of the health care team. While the ideal ICU-RC model provides
a holistic treatment approach to the ICU survivor's recovery, it is inev-
itable that all needs may not be adequately achieved through
resources of the clinic. Through these patient-clinical pharmacist rela-
tionships, ICU-RC clinical pharmacists may be first to identify such
needs. Examples may include recommending referrals to psychiatry
for co-morbid psychiatric diagnoses or to a clinical nutritionist for mal-
nutrition or an inadequate nutrition plan.
2.2.6 | Education to other health care
professionals and learners
In 2012, SCCM released a report on the state of PICS and PICS-F in
the U.S. identifying major gaps in knowledge regarding these compli-
cations, not only among the general public but also among health care
and social service professionals and their learners.4 The statement
called for increased awareness of PICS and PICS-F among these pro-
fessionals. Additionally, providing increased awareness in the process
of ICU recovery is crucial. Outpatient health care professionals may
lack the knowledge they need to guide patients through ICU recovery,
and identify and care for patients and caregivers who suffer from PICS
and PICS-F. An ICU-RC clinical pharmacist is well positioned to pro-
vide education regarding ICU recovery, and PICS management and its
complications to these health care professionals. In addition to provid-
ing education on PICS management and its complications, inpatient
ICU professionals should be educated on preventative measures that
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should be taken to reduce the risk of PICS, such as ICU protocols with
the ABCDEF bundle (A, assess, prevent, and manage pain; B, both
spontaneous awakening and spontaneous breathing trials; C, choice
of analgesic and sedation; D, delirium: assess, prevent, and manage; E,
early mobility and exercise; and F, family engagement and empower-
ment).46 Critical care clinical pharmacists are well positioned to pro-
vide education on the importance of ICU protocols and to also
maintain adherence to these protocols. This is a proven role of critical
care clinical pharmacists in improving compliance with ICU protocols
which prevent long-term functional disabilities associated with
PICS.47-50
2.2.7 | Other ICU-RC related activities
Other specific ICU-RC related activities of an ICU-RC clinical pharma-
cist includes: 1. Development of inclusion criteria for ICU-RC, 2. Assist
in screening patients during inpatient ICU rounds, 3. Identify risk fac-
tors associated with PICS, and 4. Select patients for the clinic. Patient
selection for the clinic is often based upon identification of risk factors
for PICS including mechanical ventilation, vasopressor requirements,
receipt of neuromuscular blockade, episode(s) of delirium during inpa-
tient stay, and prolonged ICU stay.13 While inclusion criteria for which
patients are seen within the ICU-RC may vary between institutions,
efforts should be made to determine which patients may benefit the
most from ICU-RCs.
Additionally, much remains to be learned about medication risks
and needs in ICU survivors and caregivers. Clinical pharmacists' roles
in medication management following critical illness needs to be evalu-
ated in large, multicenter, global studies. Further research needs to be
conducted and potential areas of research are listed in Table 3.
3 | DEVELOPING A POSITION PROPOSAL
FOR THE ICU-RC CLINICAL PHARMACIST
The proposal for the ICU-RC clinical pharmacist position should
include a clear definition of the position which consists of the justifi-
cation of the position, specific functions and responsibilities (outlined
previously), and budget considerations. Justification of the position
should include: 1. Description of the rationale and significance of the
patient care problem, including existing gaps in care, 2. Evaluation of
institutional data on ICU survivors, if available, 3. Review of institu-
tional and department of pharmacy mission statements, and 4. Review
of organizational statements that support the need for expanding
pharmacy services. As described previously, ICU survivors face many
gaps in care and these present unique opportunities for clinical phar-
macy service development in the area of ICU recovery. In addition to
gaps in care, consider requesting institutional data showing annual
ICU admission and readmission rates to the hospital attributed to
these patients.
Review of various statements (institutional, departmental, and
organizational) should be included in the proposal. Review of
institutional and department of pharmacy mission statements may
reveal important terminology useful in justification of the position.
Recommendations provided by organizations, such as the Meaningful
Use Criteria, SCCM Thrive, and Centers for Medicare and Medicaid
Services (CMS), can be used as justification for an ICU-RC clinical
pharmacist position.15,51 Meaningful use is criteria for the use of elec-
tronic health records (EHRs) and the goal is “to promote the spread of
[EHRs] to improve health care in the United States”.51 Clinical phar-
macists in ICU-RCs can help institutions meet their meaningful use
criteria through developing clinical decision support and clinical qual-
ity measures with medication-related criteria, focusing on transitions
of care and gaps in care, evaluating immunizations, and providing
timely medication reconciliation.51 A useful resource supporting the
need for ICU-RC care is the SCCM THRIVE website.15 The CMS
requirement continues to evolve and includes metrics for coordinated
care, transitions of care, and documentation of clinical reconciliation
within EHRs. A clinical pharmacist participation in a dedicated ICU-RC
will be an important contributor to these metrics including medication
reconciliation and immunizations.
In addition to organizational statements, the growing body of evi-
dence in CMM is an excellent source of data to justify an ICU-RC clin-
ical pharmacist position.52 The American College of Clinical Pharmacy
(ACCP), the American Association of Colleges of Pharmacy, and the
College of Psychiatric and Neurologic Pharmacists have invested
resources to fund research, education, and practice initiatives
supporting implementation of CMM.53 Useful resources for justifica-
tion of ICU-RC clinical pharmacist positions are outlined in Table 4.
Within the ICU-RC clinical pharmacist position proposal, it is impor-
tant to also include budget and cost considerations associated with the
position. It will be necessary to detail projected costs including salary/
hour and total hours for a clinical pharmacist (or percent effort). These
costs should be compared with projections of relatable costs incurred
from PICS, ICU recovery, and readmissions. This may require additional
information on either local readmissions related to MRPs, or citing publi-
shed literature. Additionally, a return on investment strategy should be
developed including annual milestones and metrics designed collabora-
tively with administrators. Prior to engaging management, work with
physician and nursing staff in the clinic to design reasonable expected
outcomes over a defined time period. These team members are well
positioned to assist in identifying billable mechanisms and “value added”
(services provided that could impact medication outcomes).
TABLE 3 Research needs in intensive care unit-recovery clinics
Association of medications administered in the ICU and PICS
Long-term patient outcomes post-ICU hospital discharge
Effects of patient comorbidities and their association with medication
management during ICU recovery needs
Pharmacoeconomic impact of ICU-RC clinical pharmacist's
interventions
Impact of multiple follow-up visits with ICU survivors and caregivers
Abbreviations: ICU, intensive care unit; ICU-RC, intensive care unit-
recovery clinic; PICS, post-intensive care syndrome.
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Implementing primary care clinical pharmacy services to align
with value-based payment models has been described and could be
used for ICU-RC clinical pharmacist reimbursement discussions.54
Generally, by including a clinical pharmacist in the clinic, this will
allow other team members to focus more directly on assessment,
physical exams, and MRPs identified during the clinical pharmacist-
patient interaction. Additionally, the clinical pharmacist may be avail-
able for patient follow-up and serve as an effective triage source
during the outpatient recovery period. It is reasonable to discuss a
“buy in” period for scaling up involvement over time. It is not
uncommon for a new service to require 3 to 5 years to show a full
return on investment, so consider including annual milestones show-
ing the progress.
4 | PLANNING FOR AND
IMPLEMENTATION OF THE ICU-RC CLINICAL
PHARMACIST POSITION
Once the position proposal is approved by key stakeholders, further
planning and implementation of an ICU-RC clinical pharmacist posi-
tion should occur. During the implementation process, it is important
to: 1. Measure key metrics, 2. Outline resources needed for the posi-
tion, and 3. Evaluate and address barriers that may occur during
implementation of the position.
Implementing services within existing physician practices facili-
tates ease of communication, collaboration, and measurement of key
quality metrics. Metrics such as medication interventions per patient
encounter, medication adherence, and mortality and readmission rates
should be identified a priori and recorded routinely for continuous
quality improvement to evaluate and improve services and substanti-
ate the clinical pharmacist role. To be able to collect and evaluate
these metrics, it is crucial for ICU-RC clinical pharmacists to document
all MRPs identified and interventions conducted during their interac-
tions with patients and other health care professionals.
In addition to metrics, institutional resources to support salary
and benefits of the ICU-RC clinical pharmacist will be required.
Partnerships and job sharing with existing critical care clinical pharma-
cist positions and pharmacy school faculty can be creative solutions
to support burgeoning efforts while data is garnered to support addi-
tional resources from institutional leadership. Clinical pharmacists can
extend their patient care reach by utilizing layered learning with stu-
dent pharmacists and pharmacy residents as pharmacist extenders.
This model both enriches the learners' education and increases patient
care encounters each clinical pharmacist may have.55
Other resources should also be considered which include: ade-
quate private space to care for patients; access to electronic or paper
health records for patient information gathering and documentation
of clinical services; access to drug information resources, computer,
telephone and means of communicating recommendations to collabo-
rating health care professionals. The location of the space to care for
patients should be large enough to accommodate a patient with or
without caregiver(s). Procedures for office staff to schedule patients
and communicate patient needs to the clinical pharmacist when they
are off-site should be developed. Teleconferences provided by ICU-
RC clinical pharmacists may be an option to provide education and a
resource for patients at off hours, and/or when the clinical pharmacist
is off-site, or for patients residing in rural areas. In addition to
resources for ICU-RC clinical pharmacists, resources for ICU survivors
and caregivers should be developed and provided at the initial clinic
visit. Education materials tailored to post-ICU recovery provided by
the American Thoracic Society56 and PICS/PICS-F are necessary and
can supplement the teaching material provided by SCCM Thrive's
website.15
Barriers to effectively implementing an ICU-RC clinical pharmacist
position must be noted and overcome. Some of these barriers have
been reported in a recent study.23 Time, resource allocation, health
care professionals' awareness of clinical pharmacists' value and exper-
tise in ICU recovery, clinical pharmacists' confidence and skill, and
medical record documentation can all be potential barriers that must
be planned for and addressed. Some health care professionals may
not be aware of the clinical pharmacists' value in caring for ICU survi-
vors and caregivers. Clear communication, scope of practice, and
involvement of these health care professionals in the planning process
are important to demonstrate the value of clinical pharmacists in car-
ing for ICU survivors and caregivers and to avoid negative interac-
tions. A collaborative, interprofessional approach to the management
of PICS and ICU recovery is encouraged. Collaborative practice agree-
ments and institutional protocols could facilitate active clinical phar-
macists involved in caring for these patients. In addition to lack of
provider awareness of clinical pharmacist's value in ICU recovery, clin-
ical pharmacists may lack the expertise and confidence to manage ICU
survivors and caregivers without appropriate training or mentoring.
The costs and logistics can be substantial to develop and train these
clinical pharmacists. Suggested training and options to address clinical
competencies in ICU recovery are outlined in the next section.
Provider billing capabilities by clinical pharmacists are still limited
and can be potential barriers that must be addressed and planned
for.21 Interstate variation with respect to clinical pharmacist provider
status may dictate resources available for the provision of clinical
TABLE 4 Resources for intensive care unit-recovery clinics and
post-intensive care unit care
Connect with patients and families: https://www.sccm.org/
MyICUCare/THRIVE/Connect-With-Patients-and-Families
THRIVE: https://www.sccm.org/Research/Quality/THRIVE
Comprehensive medication management in team-based care: https://
www.accp.com/docs/positions/misc/CMM%20Brief.pdf
Figuring out comprehensive medication management: https://www.
aacp.org/article/figuring-out-comprehensive-medication-
management
Comprehensive medication management (CMM) guide: https://cpnp.
org/guideline/cmm
Critical care pharmacy: https://www.bpsweb.org/bps-specialties/
critical-care-pharmacy/
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services. In addition to provider status, prescriptive privilege is an
expanded area of a pharmacist's scope of practice but can vary
between institutions. For example, clinical pharmacists practicing in
the Veterans Affairs Health System may have additional prescriptive
privileges with scope of practice. Many opportunities for collaborative
practice exist for all clinical pharmacists within existing provider prac-
tice models; yet clinical pharmacists will be called to prove their value
in cost avoidance, patient experience, and clinical outcome metrics to
substantiate their salary. It can be done but does require time to show
outcomes.22
Potential solutions could be implemented to address some of these
barriers. As health care systems transition from fee-for-service to
value-based care, when clinical pharmacists document their interven-
tions and outcomes successfully, positions can be successfully substan-
tiated through collaborative practice. Interprofessional collaboration
will be essential to ensure the success of the patient, entire clinical
team, and viability of the health care system as a whole. Efforts to opti-
mize care transitions are paramount as models of care are redesigned
to emphasize home-based care. Clinical pharmacists in ICU-RCs are
uniquely poised to play a pivotal role in this transition.22,57
5 | COMPETENCY AND TRAINING OF THE
ICU-RC CLINICAL PHARMACIST
Clinical pharmacists may lack the expertise and confidence to manage
ICU survivors and caregivers without appropriate training or men-
toring. Clinical pharmacists providing care to ICU survivors and care-
givers should demonstrate competency in the knowledge and skills to
serve this unique population. Suggested training and competencies of
the ICU-RC clinical pharmacist are outlined in Table 5. Postgraduate
training will provide a foundation for providing clinical services to
patients in various settings. However, specific experiences in caring
for ICU survivors and caregivers may be limited or not available
throughout postgraduate training. Therefore, it is crucial for postgrad-
uate training, especially critical care pharmacy residency programs, to
include experiences and opportunities to care for these patients. The
experiences could include required rotations in ICU-RCs (if available)
or ambulatory care transitions of care pharmacy services with a focus
on ICU survivors. If these opportunities are not available during post-
graduate training, clinical pharmacists should be provided the oppor-
tunity to shadow established ICU-RC clinical pharmacists, or at a
minimum, provide other experiences (ie, conference programming on
ICU recovery) to ensure that clinical pharmacists obtain essential
information before providing proficient pharmaceutical care to these
patients and caregivers. Training or mentoring by an ICU-RC clinical
pharmacist is ideal.
In addition to training, board certification by the Board of Phar-
macy Specialties in Critical Care Pharmacy or associated specialty is
strongly preferred. The path to board certification is outlined on the
Board of Pharmacy Specialties website58 (see Table 4 for the website).
Additionally, clinical pharmacists should demonstrate excellent com-
munication and interpersonal skills, especially in working as part of an
interprofessional team. Active participation in professional societies
leading the development of this clinical realm, such as ACCP and
SCCM, is essential for a candidate's professional and practice
development.
6 | CONCLUSIONS
Due to ICU survivors' health complexity and challenges associated
with their care, clinical pharmacist involvement in ICU-RCs is crucial.
There is a shortage of clinicians to manage and treat ICU survivors and
caregivers, and this gap in the health care system is an opportunity for
increased involvement by clinical pharmacists. Additionally, the field
of ICU recovery is rapidly evolving, and an interprofessional approach
will be required to judiciously, and effectively, guide treatment of ICU
survivors and caregivers. Clinical pharmacists in ICU-RCs can play a
critical role within the interprofessional team to promote education on
PICS and PICS-F, improve medication adherence, facilitate appropriate
referrals to PCPs and specialists, ensure CMMs and medication recon-
ciliation, provide assessment of inappropriate and appropriate medica-
tions after hospitalization, address ADEs, MEs, and drug interactions,
promote preventive measures, and facilitate medication acquisition
and logistics with the goal of improving patient outcomes and reduc-
ing health care system costs. With the expanding role of clinical phar-
macists through collaborative practice agreements, provider
designations, and billing privileges, clinical pharmacists practicing
within ICU-RCs will continue to expand and evolve.
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TABLE 5 Suggested training and competencies of the intensive
care unit-recovery clinics clinical pharmacist
Training and competencies
Post-graduate year 1 pharmacy practice residency in a hospital setting
Post-graduate year 2 critical care pharmacy residency
Board certification in critical care medicine or associated specialty
Other clinical competencies
Comprehensive medication management and consideration in the
context of ICU recovery
Risk factors associated with, identification of and management of
PICS/PICS-F
ICU recovery process and complications related to recovery
Evaluation of and management of mental health conditions
Evaluation of and management of cognitive impairment
Abbreviations: ICU, intensive care unit; PICS, post-intensive care syn-
drome; PICS-F, post-intensive care syndrome family.
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